Literature DB >> 17215445

Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study.

Keattiyoat Wattanakit1, Aaron R Folsom, Elizabeth Selvin, Josef Coresh, Alan T Hirsch, Beth D Weatherley.   

Abstract

Chronic kidney disease (CKD) is associated with an increased risk for cardiovascular disease, but its association with peripheral arterial disease (PAD) is unclear. With the use of data from the Atherosclerosis Risk in Communities (ARIC) Study, 14,280 middle-aged adults were categorized on the basis of estimated GFR >/=90, 60 to 89, and 15 to 59 ml/min per 1.73 m(2) for normal kidney function, mildly decreased kidney function, and stages 3 to 4 CKD, respectively. Incident PAD was defined as a new onset of ankle-brachial index <0.9 assessed at regular examinations, new intermittent claudication assessed by annual surveillance, or PAD-related hospital discharges. Incidence rates and relative risks (RR) for PAD were compared across these categories. During a mean follow-up time of 13.1 yr (186,616 person-years), 1016 participants developed PAD. The incidence rates per 1000 person-years were 4.7, 4.9, and 8.6 for the normal kidney function, mildly decreased kidney function, and CKD groups, respectively. Compared with participants with normal kidney function, the age-, gender-, race-, and ARIC field center-adjusted RR for PAD was 1.04 (95% confidence interval [CI] 0.91 to 1.18) for those with mildly decreased kidney function and 1.82 (95% CI 1.34 to 2.47) for those with CKD. After additional adjustment for cardiovascular disease risk factors, an increase in risk for incident PAD still was observed in participants with CKD, with a multivariable adjusted RR of 1.56 (95% CI 1.13 to 2.14). Patients with CKD are at increased risk for incident PAD. Development of strategies for screening and prevention of PAD in this high-risk population seems warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215445     DOI: 10.1681/ASN.2005111204

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  82 in total

Review 1.  Diabetic foot disease in people with advanced nephropathy and those on renal dialysis.

Authors:  Agbor Ndip; Lawrence A Lavery; Andrew J M Boulton
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

2.  Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Hisatomi Arima; Johan Ärnlöv; Massimo Cirillo; Natalie Ebert; Jade S Hiramoto; Heejin Kimm; Michael G Shlipak; Frank L J Visseren; Ron T Gansevoort; Csaba P Kovesdy; Varda Shalev; Mark Woodward; Florian Kronenberg
Journal:  Lancet Diabetes Endocrinol       Date:  2017-07-14       Impact factor: 32.069

3.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

Review 4.  Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis.

Authors:  Joe F Lau; Mitchell D Weinberg; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

5.  Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Kunihiro Matsushita; Elizabeth Selvin; Lori D Bash; Brad C Astor; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2010-02-26       Impact factor: 8.860

Review 6.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

7.  Dietary intake and peripheral arterial disease incidence in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Rachel P Ogilvie; Pamela L Lutsey; Gerardo Heiss; Aaron R Folsom; Lyn M Steffen
Journal:  Am J Clin Nutr       Date:  2017-01-11       Impact factor: 7.045

8.  Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Ning Ding; Lucia Kwak; Shoshana H Ballew; Bernard Jaar; Ron C Hoogeveen; Christie M Ballantyne; A Richey Sharrett; Aaron R Folsom; Gerardo Heiss; Maya Salameh; Josef Coresh; Alan T Hirsch; Elizabeth Selvin; Kunihiro Matsushita
Journal:  Atherosclerosis       Date:  2018-04-30       Impact factor: 5.162

9.  Low ankle-brachial index and the development of rapid estimated GFR decline and CKD.

Authors:  Meredith C Foster; Nimrta Ghuman; Shih-Jen Hwang; Joanne M Murabito; Caroline S Fox
Journal:  Am J Kidney Dis       Date:  2012-08-15       Impact factor: 8.860

10.  Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA).

Authors:  K Wattanakit; A R Folsom; M H Criqui; H J Kramer; M Cushman; S Shea; A T Hirsch
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.